Sleep Apnea Pill Reduced Breathing Interruptions
A phase 3 trial found that AD109 (aroxybutynin and atomoxetine) reduced breathing interruptions and improved oxygen levels in patients with obstructive sleep apnea.
Tag: Apnimed
Sleep Apnea Pill Reduced Breathing Interruptions
A phase 3 trial found that AD109 (aroxybutynin and atomoxetine) reduced breathing interruptions and improved oxygen levels in patients with obstructive sleep apnea.
Read More
Apnimed Pulse Oximeter Can Monitor OSA Treatment Response
A wearable pulse oximeter and connected software platform from Apnimed show promise for monitoring obstructive sleep apnea (OSA) and other sleep-related breathing diseases.
Read More
Enrollment Completed Early for Phase 3 Trial of Oral Sleep Apnea Pill
Apnimed announced the early completion of enrollment for its phase 3 trial to evaluate the efficacy and safety of AD109 for obstructive sleep apnea.
Read More
FDA Grants Fast Track Designation to Apnimed Sleep Apnea Drug Candidate AD109
The US FDA has granted Fast Track designation for Apnimed’s oral pharmacologic AD109 for the treatment of obstructive sleep apnea (OSA).
Read More
Apnimed’s Second Core Sleep Apnea Drug Candidate, AD504, Lowers AHI
Apnimed shared data from a proof-of-concept study exploring two potential oral therapeutic candidates for the treatment of patients with obstructive sleep apnea.
Read More